The Chinese herb-derived Sparstolonin B suppresses HIV-1 transcription

Virology Journal

Volumn 12, Issue 1, 2015, Pages

  Deng, Xin ^a   Zhang, Yaping ^a   Jiang, Feng ^a   Chen, Ran ^a   Peng, Peichun ^a   Wen, Bin ^a   Liang, Jian ^a  

^a RUIKANG HOSPITAL AFFILIATED TO GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

HIV transcription; Sparstolonin B; TAR region

Indexed keywords

ANTIVIRUS AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; SPARSTOLONIN B; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL PRODUCT; FUSED HETEROCYCLIC RINGS;

ANTIVIRAL ACTIVITY; ARTICLE; CC50; CHINESE HERB; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IN VITRO STUDY; VIRUS INHIBITION; VIRUS TRANSCRIPTION; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENETIC TRANSCRIPTION; ISOLATION AND PURIFICATION; MEDICINAL PLANT; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; BIOLOGICAL PRODUCTS; CELLS, CULTURED; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIV-1; HUMANS; PLANTS, MEDICINAL; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; VIRUS REPLICATION; ZIDOVUDINE;

EID: 84937783557     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-015-0339-8     Document Type: Article

References (19)

1. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61(2):213-22.
2. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 1991;254(5030):423-7.
3. McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, et al. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol. 1985;135(5):3151-62.
4. Ganesh L, Burstein E, Guha-Niyogi A, Louder MK, Mascola JR, Klomp LW, et al. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature. 2003;426(6968):853-7. doi: 10.1038/nature02171.
5. Qiu C, Xu X. H. Z. Pharmacology and clinics of Chinese material. Medica. 2008;14.
6. Lee SY, Choi SU, Lee JH, Lee DU, Lee KR. A new phenylpropane glycoside from the rhizome of Sparganium stoloniferum. Arch Pharm Res. 2010;33(4):515-21. doi: 10.1007/s12272-010-0404-1.
7. Liang Q, Wu Q, Jiang J, Duan J, Wang C, Smith MD, et al. Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011;286(30):26470-9. doi: 10.1074/jbc.M111.227934.
8. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46(6):1896-905.
9. Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, Gaynor RB. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. Embo J. 1989;8(3):765-78.
10. Southgate CD, Green MR. The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev. 1991;5(12B):2496-507.
11. Shridhar V, Chen Y, Gupta P. The CD8 antiviral factor (CAF) can suppress HIV-1 transcription from the long terminal repeat (LTR) promoter in the absence of elements upstream of the CATATAA box. Virol J. 2014;11:130. doi: 10.1186/1743-422X-11-130.
12. Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, et al. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA. 1989;86(18):6925-9.
13. Weeks KM, Ampe C, Schultz SC, Steitz TA, Crothers DM. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science. 1990;249(4974):1281-5.
14. Roy S, Delling U, Chen CH, Rosen CA, Sonenberg N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev. 1990;4(8):1365-73.
15. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010;85(1):1-18. doi: 10.1016/j.antiviral.2009.10.002.
16. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-6. doi: 10.1158/0008-5472.CAN-09-1947.
17. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47(2):331-85.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
19. Eron Jr. JJ, Johnson VA, Merrill DP, Chou TC, Hirsch MS. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother. 1992;36(7):1559-62.